^
Association details:
Evidence:
Evidence Level:
Resistant: B - Late Trials
Title:

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase 3 REFLECT Study

Published date:
06/09/2021
Excerpt:
407 patients were included in the serum analysis set (lenvatinib n=279, sorafenib n=128); 58 patients were included in the gene-expression analysis set (lenvatinib n=34, sorafenib n=24)….Higher baseline VEGF, ANG2, and FGF21 correlated with shorter OS in both treatment groups.
DOI:
10.1158/1078-0432.CCR-20-4219
Trial ID: